A deadly superbug resistant to all forms of antibiotics has arrived in the U.S. which researchers say may signal the “end of the road” for all antibiotics in the future.
Researchers detected the superbug in a 49-year-old Pennsylvania woman who tested positive for carrying the deadly bacteria.
Defense Department researchers determined that she carried a strain of E. coli resistant to the antibiotic colistin, according to a study published Thursday in Antimicrobial Agents and Chemotherapy, a publication of the American Society for Microbiology. The authors wrote that the discovery “heralds the emergence of a truly pan-drug resistant bacteria.”
Colistin is the antibiotic of last resort for particularly dangerous types of superbugs, including a family of bacteria known as carbapenem-resistant Enterobacteriaceae, or CRE, which health officials have dubbed “nightmare bacteria.” In some instances, these superbugs kill up to 50 percent of patients who become infected. The Centers for Disease Control and Prevention has called CRE among the country’s most urgent public health threats.
Health officials said the case in Pennsylvania, by itself, is not cause for panic. The strain found in the woman is treatable with some other antibiotics. But researchers worry that the antibiotic-resistant gene found in the bacteria, known as mcr-1, could spread to other types of bacteria that can already evade other types of antibiotics.
It’s the first time this colistin-resistant strain has been found in a person in the United States. In November, public health officials worldwide reacted with alarm when Chinese and British researchers reported finding the colistin-resistant strain in pigs, raw pork meat and in a small number of people in China. The deadly strain was later discovered in Europe, Africa, South America and Canada.
“It basically shows us that the end of the road isn’t very far away for antibiotics — that we may be in a situation where we have patients in our intensive-care units, or patients getting urinary tract infections for which we do not have antibiotics,” CDC Director Tom Frieden said in an interview Thursday.
“I’ve cared for patients for whom there are no drugs left. It is a feeling of such horror and helplessness,” Frieden added. “This is not where we need to be.”
Separately, researchers at the U.S. Department of Agriculture and the Health and Human Services Department reported that testing of hundreds of livestock and retail meats turned up the same colistin-resistent bacteria in a sample from a pig intestine in the United States. The USDA said it is working to determine the pig’s farm of origin.
CDC officials are working with Pennsylvania health authorities to interview the patient and family to identify how she may have contracted the bacteria, including reviewing recent hospitalizations and other health-care exposures. CDC hopes to screen the woman and her contacts to see if others might be carrying the organism. Local and state health departments also will be collecting cultures as part of the investigation.
Thursday’s study did not disclose further details about the Pennsylvania woman or the outcome of her case, although it said that she had not reported any travel in the previous five months. The authors could not be reached for comment. A spokeswoman for Pennsylvania Department of Health said the agency could not legally disclose specific details about an individual case investigation.
Pennsylvania Gov. Tom Wolf issued a statement saying his administration immediately began working with the CDC and Department of Defense to coordinate “an appropriate and collaborative” response.
“We are taking the emergence of this resistance gene very seriously,” he said, adding that authorities will take all necessary actions to prevent it from becoming a widespread problem with “potentially serious consequences.”
Sen. Robert P. Casey Jr. (D-Pa.) said he is concerned about the reports. In a statement, Casey said he supported legislation for and participated in hearings about antibiotic-resistant bacteria, which he said “present an urgent public health problem that we must focus on intensively.”
Infectious disease experts say the antibiotic-resistant gene, which can be transferred from bacteria to bacteria, has been found mostly in livestock but also in humans. It is likely leaping from livestock to humans through food, said Yohei Doi, an infectious disease doctor at the University of Pittsburgh who has studied the problem.
“Food handlers may be at higher risk,” he said. In places like China, where live animal markets are often in close proximity to food stalls, it may be more likely for the bacteria to spread from animals to humans. In the United States, where food is sealed in packages and containers, it’s a different story, he said.
“These are the reasons why I don’t think we need to panic,” Doi said. “But it does tell us that this concerning gene is in the United States and we need to find out what the extent of the problem is.”
He and other infectious disease experts called for speedier action to curb the overuse of antibiotics in livestock.
“It’s hard to imagine worse news for public health in the United States,” Lance Price, director of the Antibiotic Resistance Action Center and a George Washington University professor said in a statement Thursday about the Pennsylvania case. “We may soon be facing a world where CRE infections are untreatable.”
Colistin is widely used in Chinese livestock and this use likely led to the evolution of the resistance gene, he said. Scientists rang the alarm bells about the gene in November, but not enough attention was paid. “Now we find that this gene has made its way into pigs and people in the U.S.,” Price said. “If our leaders were waiting to act until they could see the cliff’s edge—I hope this opens their eyes to the abyss that lies before us.”
Scientists and public health officials have long warned that if the resistant bacteria continue to spread, treatment options could be seriously limited. Routine operations could become deadly. Minor infections could become life-threatening crises. Pneumonia could be more and more difficult to treat.
Already, doctors had been forced to rely on colistin as a last-line defense against antibiotic-resistant bacteria. The drug is hardly ideal. It is more than half a century old and can seriously damage a patient’s kidneys. And yet, because doctors have run out of weapons to fight a growing number of infections that evade more modern antibiotics, it has become a critical tool in fighting off some of the most tenacious infections.
Bacteria develop antibiotic resistance in two ways. Many acquire mutations in their own genomes that allow them to withstand antibiotics, although that ability can’t be shared with pathogens outside their own family.
Other bacteria rely on a shortcut: They get infected with something called a plasmid, a small piece of DNA, carrying a gene for antibiotic resistance. That makes resistance genes more dangerous because plasmids can make copies of themselves and transfer the genes they carry to other bugs within the same family as well as jump to other families of bacteria, which can then “catch” the resistance directly without having to develop it through evolution.
The colistin-resistant E. coli found in the Pennsylvania woman has this type of resistance gene.
Public health officials say they have expecting this resistance gene to turn up in the United States.
“This is definitely alarming,” said David Hyun, a senior officer leading an antibiotic-resistance project at the Pew Charitable Trust. “The fact that we found it in the United States confirms our suspicions and adds urgency to actions we need to work on antibiotic stewardship and surveillance for this type of resistance.”
Late last year, as part of a broader budget deal, Congress agreed to give hundreds of millions of dollars to the federal agencies engaged in the battle against antibiotic-resistant bacteria.
The largest chunk of that money, more than $150 million, was slated to go to the CDC as part of an effort to build and strengthen capacity at state and local health departments to prevent and monitor superbug outbreaks.
Other funding went to the National Institutes of Health for research on combating antimicrobial resistance, as well as to an agency known as BARDA, which works on national preparedness for chemical and biological threats, including developing new therapies.